CD200 antibodies

CD200 antibodies

Clone: OX-104
OX-104 reacts with the human CD200 antigen, also known as MRC, MOX1/2, and OX-2, a type-1 membrane glycoprotein, which contains two immunoglobulin domains. Studies of the related gene in mouse and rat suggest that CD200 may regulate myeloid cell activity and delivers an inhibitory signal for the macrophage lineage in diverse tissues. CD200 may serve as a cancer stem cell marker as co-expression with other reported stem cell markers was found on prostate, breast, brain, and colon cancers. In addition, CD200 expression was shown to be a prognostic factor in AML and multiple myeloma.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis. Expression of CD200 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Alternative Names

OX2, MRC, MOX1/2

Technical specifications

  • Antigen: CD200
  • Clone: OX-104
  • Isotype: mouse IgG1κ
  • Alternative names of antigen: OX2, MRC, MOX1/2
  • Molecular mass of antigen [kDa]: 28
  • Distribution of antigen: B cells, dendritic cells, endothelial cells, mesenchymal stem cells, neurons, ES and iPS cells, smooth muscle, T cells, thymocytes
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: APC
  • Selected References

    1. Moreaux, J. et al. (2007) CD200 as a prognostic factor in acute myeloid leukemia. Blood 108: 4194-4197
    2. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
    3. Minas, K. et al. (2006) Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit. Rev. Immunol. 26: 213-230
    4. Mason, D. et al. (2002) Leucocyte typing VII. Oxford, Oxford University Press
    5. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
    6. Tonks, A. et al. (20007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21: 566-568
    7. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
    8. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
    9. Kawasaki, B. T. et al. (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 364: 778-782
    10. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of Immunologically Defined Cell Populations by Flow Cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  • Brochures and posters

  • Certificates of Analysis (CoA)

    Please follow this
    link
    to search for certificates by lot number.
Product options: 1

Product information

Size
Order no.
Price

CD200-APC

  • OX-104
  • CE–IVD
for 100
tests
170-078-042
EUR 530,00